Following closely was ARK’s investment in Tempus AI Inc (TEM), where the firm bought 158,051 shares across its ARKK and ARKG ETFs, totaling $8,833,470. This purchase continues a recent trend of ARK ...

AI could inject an additional $461 billion into the healthcare sector by 2035, according to Accenture, as it races past the ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

This marks the second FDA-cleared ECG-AI device in Tempus’ cardiovascular product suite, following its previously cleared Tempus ECG-AF solution. The new software analyzes resting, non-ambulatory ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Detectives in Olomouc have used AI to create a probable image of the murderer of a video-rental employee in 2005. From the original facial composite, they have created a probable image of the ...

Tempus AITEM reached an important technical milestone, with its Relative Strength (RS) Rating moving into the 90-plus ...

GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights. Read why I am bullish about WGS stock.

Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the ...

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors of ...

Last week, readers were most interested in a story about an extended collaboration between Personalis and Tempus to include colorectal cancer.